Table 1 Sample characteristics and characteristics of anabolic androgenic steroids (AAS) use
From: Sleep pathology and use of anabolic androgen steroids among male weightlifters in Norway
Variable | WLC, N = 581 | AAS, N = 681 | Test Statistic | p-value2 | η2 |
|---|---|---|---|---|---|
Age | 37 (9) | 38 (11) | 0.01 | > 0.9 | −0.008 |
Edu | 16.76 (2.64) | 14.95 (2.54) | 15 | < 0.001 | 0.114 |
IQ | 117 (9) | 108 (10) | 21 | < 0.001 | 0.158 |
Height | 182 (6) | 182 (7) | 0.02 | 0.9 | −0.008 |
Weight | 93 (11) | 100 (17) | 5.8 | 0.016 | 0.039 |
Strength training (min/week) | 382 (210) | 356 (210) | 0.40 | 0.5 | −0.005 |
Endurance training (min/week) | 101 (130) | 100 (155) | 1.0 | 0.3 | 0.000 |
Bench max | 142 (22) | 175 (35) | 29 | < 0.001 | 0.225 |
Total years AAS use | NA (NA) | 11 (8) | |||
Debut age | NA (NA) | 23 (8) | |||
Current/previous AAS use | |||||
Current | 0 / 0 (NA%) | 44 / 68 (65%) | |||
Previous | 0 / 0 (NA%) | 24 / 68 (35%) | |||
Anxiety medication3 | 4 / 58 (6.9%) | 15 / 664 (23%) | 0.023 | ||
Antidepressants3 | 4 / 58 (6.9%) | 17 / 664 (26%) | 0.007 | ||
Sleeping medication3 | 4 / 58 (6.9%) | 25 / 664 (38%) | < 0.001 | ||
Sleeping problems as side-effect of AAS use | |||||
No problems | 0 / 0 (NA%) | 22 / 655 (34%) | |||
Some degree | 0 / 0 (NA%) | 22 / 655 (34%) | |||
Certain degree | 0 / 0 (NA%) | 17 / 655 (26%) | |||
Large degree | 0 / 0 (NA%) | 4 / 655 (6%) | |||
HSCL total | 1.22 (0.28) | 1.42 (0.43) | 11.25 | < 0.001 | 0.083 |
HSCL anxiety | 1.15 (0.26) | 1.36 (0.45) | 10.61 | 0.001 | 0.078 |
HSCL depression | 1.26 (0.33) | 1.45 (0.45) | 8.63 | 0.003 | 0.06 |